BACKGROUND:Breast magnetic resonance imaging (MRI) has shown high sensitivity in determining tumor extent, multifocality, and occult contralateral breast cancer. Low specificity, unnecessary mastectomies, and costs are arguments against MRI. The purpose of this study was to determine whether preoperative breast MRI would affect primary surgical management, reduce reexcision/reoperation procedures, and influence the choice of neoadjuvant treatment in patients with newly diagnosed breast cancer. METHODS: This prospective, randomized, multicenter study included 440 breast cancer patients younger than aged 56 years from three, Swedish, large-volume breast units. Patients were randomly allocated on a 1:1 basis to either preoperative staging with breast MRI (n = 220) or no breast MRI (n = 220) (control group). Treatment planning of all patients was discussed at multidisciplinary team conferences. RESULTS: In patients randomized to the MRI group, who had an observed higher percentage of planned breast-conserving surgery (BCS) compared with the control group, a change from suggested breast conservation to mastectomy occurred in 23 of 153 (15 %) patients. Breast MRI provided additional information in 83 of 220 (38 %) patients, which caused a change in treatment plan in 40 (18 %). The breast reoperation rate was significantly lower in the MRI group: 11 of 220 (5 %) versus 33 of 220 (15 %) in the control group (p < 0.001). The number of mastectomies, axillary reoperations, and the number of patients receiving neoadjuvant chemotherapy after definitive treatment did not differ significantly between the groups. CONCLUSIONS:Preoperative staging with breast MRI in women younger than age 56 years altered the treatment plan in 18 % of the patients. Although a higher MRI-related conversion rate from breast conservation to mastectomy was found, the final numbers of mastectomies did not differ between the two groups. The breast reoperation rate in the MRI group was significantly reduced.
RCT Entities:
BACKGROUND: Breast magnetic resonance imaging (MRI) has shown high sensitivity in determining tumor extent, multifocality, and occult contralateral breast cancer. Low specificity, unnecessary mastectomies, and costs are arguments against MRI. The purpose of this study was to determine whether preoperative breast MRI would affect primary surgical management, reduce reexcision/reoperation procedures, and influence the choice of neoadjuvant treatment in patients with newly diagnosed breast cancer. METHODS: This prospective, randomized, multicenter study included 440 breast cancerpatients younger than aged 56 years from three, Swedish, large-volume breast units. Patients were randomly allocated on a 1:1 basis to either preoperative staging with breast MRI (n = 220) or no breast MRI (n = 220) (control group). Treatment planning of all patients was discussed at multidisciplinary team conferences. RESULTS: In patients randomized to the MRI group, who had an observed higher percentage of planned breast-conserving surgery (BCS) compared with the control group, a change from suggested breast conservation to mastectomy occurred in 23 of 153 (15 %) patients. Breast MRI provided additional information in 83 of 220 (38 %) patients, which caused a change in treatment plan in 40 (18 %). The breast reoperation rate was significantly lower in the MRI group: 11 of 220 (5 %) versus 33 of 220 (15 %) in the control group (p < 0.001). The number of mastectomies, axillary reoperations, and the number of patients receiving neoadjuvant chemotherapy after definitive treatment did not differ significantly between the groups. CONCLUSIONS: Preoperative staging with breast MRI in women younger than age 56 years altered the treatment plan in 18 % of the patients. Although a higher MRI-related conversion rate from breast conservation to mastectomy was found, the final numbers of mastectomies did not differ between the two groups. The breast reoperation rate in the MRI group was significantly reduced.
Authors: G N Rodenko; S E Harms; J M Pruneda; R S Farrell; W P Evans; D S Copit; P A Krakos; D P Flamig Journal: AJR Am J Roentgenol Date: 1996-12 Impact factor: 3.959
Authors: N H G M Peters; S van Esser; M A A J van den Bosch; R K Storm; P W Plaisier; T van Dalen; S C E Diepstraten; T Weits; P J Westenend; G Stapper; M A Fernandez-Gallardo; I H M Borel Rinkes; R van Hillegersberg; W P Th M Mali; P H M Peeters Journal: Eur J Cancer Date: 2010-12-30 Impact factor: 9.162
Authors: P J Drew; L W Turnbull; S Chatterjee; J Read; P J Carleton; J N Fox; J R Monson; M J Kerin Journal: Ann Surg Date: 1999-11 Impact factor: 12.969
Authors: Cristina M Checka; Jennifer E Chun; Freya R Schnabel; Jiyon Lee; Hildegard Toth Journal: AJR Am J Roentgenol Date: 2012-03 Impact factor: 3.959
Authors: Wendie A Berg; Lorena Gutierrez; Moriel S NessAiver; W Bradford Carter; Mythreyi Bhargavan; Rebecca S Lewis; Olga B Ioffe Journal: Radiology Date: 2004-10-14 Impact factor: 11.105
Authors: Isabelle Bedrosian; Rosemarie Mick; Susan G Orel; Mitchell Schnall; Carol Reynolds; Francis R Spitz; Linda S Callans; Gordon P Buzby; Ernest F Rosato; Douglas L Fraker; Brian J Czerniecki Journal: Cancer Date: 2003-08-01 Impact factor: 6.860
Authors: T Onega; W Zhu; J E Weiss; M Goodrich; A N A Tosteson; W DeMartini; B A Virnig; L M Henderson; D S M Buist; K J Wernli; K Kerlikowske; R A Hubbard Journal: Breast Cancer Res Treat Date: 2018-03-07 Impact factor: 4.872
Authors: Rebekah H Griesenauer; Jared A Weis; Lori R Arlinghaus; Ingrid M Meszoely; Michael I Miga Journal: J Med Imaging (Bellingham) Date: 2018-02-08
Authors: Elizabeth T Loggers; Hongyuan Gao; Laura S Gold; Larry Kessler; Ruth Etzioni; Diana Sm Buist Journal: J Comp Eff Res Date: 2015-05-11 Impact factor: 1.744
Authors: Gerald Gui; Effrosyni Panopoulou; Sarah Tang; Dominique Twelves; Mohammed Kabir; Ann Ward; Catherine Montgomery; Ashutosh Nerurkar; Peter Osin; Clare M Isacke Journal: Breast Cancer Res Treat Date: 2021-01-04 Impact factor: 4.872
Authors: Monica Morrow; Sarah T Hawley; M Chandler McLeod; Ann S Hamilton; Kevin C Ward; Steven J Katz; Reshma Jagsi Journal: Ann Surg Oncol Date: 2017-03-22 Impact factor: 4.339